Drugs / SPECTRUM cigarettes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05707871 | Apr 2023 → Dec 2026 expected | nicotine dependence | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02951143 | Jan 2017 → Nov 2019 | substance-related disorder | Virginia Polytechnic Institute and State University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02870218 Comparator | May 2019 → Jul 2021 | nicotine dependence | Rose Research Center, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPECTRUM cigarettes | “Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.” NCT02870218 ↗ |
| Route | Inhaled | “smoke 0.40mg nicotine Spectrum cigarettes” NCT02870218 ↗ |